Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02327078 · OUTCOME

Phase 2: Overall Survival (OS) Rate of Proportion With Glioblastoma

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) · Source last updated 2025-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
Month 9

What was measured

OS rate is defined as the proportion of participants alive 9 months after the start of treatment.

Analysis population: The Phase 2 Full Analysis Population includes all participants enrolled in the study who take at least 1 dose of study drug. The data is reported for participants with Glioblastoma cancer type for this outcome measure.

Groups in this outcome

Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg

Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg33

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg0.458Not reported0.2970.605Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.297
        upper Limit
        0.605
        value
        0.458
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    units
    Participants
description
OS rate is defined as the proportion of participants alive 9 months after the start of treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.
    id
    OG000
    title
    Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg
param Type
NUMBER
population Description
The Phase 2 Full Analysis Population includes all participants enrolled in the study who take at least 1 dose of study drug. The data is reported for participants with Glioblastoma cancer type for this outcome measure.
reporting Status
POSTED
time Frame
Month 9
title
Phase 2: Overall Survival (OS) Rate of Proportion With Glioblastoma
type
PRIMARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice